在缺血性中风模型中,用于药物向相互作用预测的混合方法
Jing-Jie Peng1, Yi-Yue Zhang2, Rui-Feng Li2
1Department of Laboratory Medicine, the third Xiangya Hospital, Central South University, Changsha 410013, China.
Artificial intelligence in medicine
|February 16, 2025
概括
一个新的框架,strokeDTI,通过分析复杂的细胞死亡途径来确定潜在的抗中风药物. 塞尔杜拉提尼布被证实是有前途的治疗剂,在中风模型中显著减少脑损伤.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 缺血性中风涉及复杂的,相互连接的细胞死亡途径,阻碍了向治疗的发展.
- 现有的药物向相互作用 (DTI) 模型因数据依赖而面临现实世界的预测准确性挑战.
研究的目的:
- 开发一种新的框架,中风DTI,用于在缺血性中风中特定疾病的DTI识别.
- 通过结合基于文献的验证,提高DTI预测的可靠性.
主要方法:
- 利用转录组测序数据构建一个激活路径的图形网络.
- 开发了中风DTI框架,集成路径分析和一个新的预测有效性模块.
- 在文献数据和用于模型改进的约束性得分之间的杆相关性.
主要成果:
- 鉴定了Cerdulatinib作为一种潜在的治疗向亡和亡的药物.
- 实验验证证了Cerdulatinib在减少中风引起的脑损伤,改善神经功能和减少心脏病发作量方面的有效性.
- 通过综合验证模块,证明了DTI预测的可靠性提高.
结论:
- 脑卒中DTI框架为特定疾病的药物标识提供了一个强大的方法.
- 塞尔杜拉提尼布显示出作为一种用于治疗缺血性中风的新疗剂的显著潜力.
相关概念视频
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


